Description
GSK-2334470 is a selective inhibitor of PDK1 that exhibits anticancer activity in in vitro models. GSK-2334470 inhibits T-loop phosphorylation of SGK and S6K1, Akt and Akt substrates GSK3, FoxO, and PRAS40, and ERK substrate RSK2.
| Product Unit Size | Cost | Quantity | Stock |
|---|
GSK-2334470 is a selective inhibitor of PDK1 that exhibits anticancer activity in in vitro models. GSK-2334470 inhibits T-loop phosphorylation of SGK and S6K1, Akt and Akt substrates GSK3, FoxO, and PRAS40, and ERK substrate RSK2.
| Cas No. | 1227911-45-6 |
|---|---|
| Purity | ≥99%, ≥99%ee |
| Formula | C25H34N8O |
| Formula Wt. | 462.59 |
| Chemical Name | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide |
| IUPAC Name | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N- cyclohexyl-6-methylpiperidine-3-carboxamide |
| Solubility | DMSO 28 mg/mL (64.6 mM) Water Insoluble Ethanol Insoluble |
| Appearance | off-white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Najafov A, Sommer EM, Axten JM, et al. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011 Jan 15;433(2):357-69. PMID: 21087210.
EGFR inhibitor.
ITC, used as chiral agent.
B-Raf, VEGFR2, c-Raf, PDGFR, CSF-1R, RET, c-Kit...
pan-Raf inhibitor.
Benzamide; HDAC1 inhibitor.
1,8-Diaza-anthracene-tetrone; JNK and ERK5 inhi...
Thienylbutyl ITC analog.
Cell membrane permeability modulator, topoisome...
Immunodominant peptide epitope occurring in mul...
Endogenous neuropeptide hormone; somatostatin a...
Cyclic peptide; calcineurin inhibitor.
Endogenous hormone involved in circadian rhythm...
Mycotoxin that has structural similarity to est...
FIASMA, SERT inhibitor, 5-HT and σ1 antagonist...
Pyrimidine nucleoside (cytidine) analog; DNA ch...
Polyketide; protein translation inhibitor, mamm...
Synthetic peptide, CDPK, PKC, CaMKII substrate....
FGFR inhibitor.
VEGFR inhibitor.